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“Black swan in the kidney”: Renal involvement in the antiphos- [5] and were recently validated [6]. In this review, we
pholipid antibody syndrome. The antiphosphospholipid anti- provide an overview of the mechanism of thrombosis in
body syndrome (APS) describes a clinical entity with recurrent APS, the spectrum of renal abnormalities encounteredthrombosis, fetal loss, thrombocytopenia in the presence of
with this syndrome, and the available treatment options.lupus anticoagulant and/or antibodies to cardiolipin. These an-
tibodies may be associated with connective tissue diseases such
as systemic lupus erythematosus (secondary APS) or be found
BIOLOGY OF ANTIPHOSPHOSPHOLIPIDin isolation (primary APS). Renal syndromes increasingly be-
ing reported in association with these antibodies include throm- ANTIBODIES
botic microangiopathy, renal vein thrombosis, renal infarction,
Antiphospholipid antibodies are a heterogeneous grouprenal artery stenosis and/or malignant hypertension, increased
of immunoglobulins directed against negatively chargedallograft vascular thrombosis, and reduced survival of renal
allografts. Although much has been understood concerning the phospholipids (such as phosphatidyl serine, or cardio-
biology of these antibodies and the pathogenesis of thrombosis, lipin), protein-phospholipid complexes, or plasma pro-
the optimal therapy remains to be elucidated. This article pre- teins such as beta 2-glycoprotein I (2-GPI). Phospho-sents a historical review of the renal involvement in the anti-
lipids play a critical role in the normal control of thephospholipid syndrome and discusses therapeutic options. Fur-
coagulation as depicted in Figure 1. For example, acti-ther research is needed.
vated protein C inactivates factors Va and factor VIIIa
in the presence of phospholipids and factor S, thus in-
hibiting the generation of thrombin [7]. APA includeIt has been more than 15 years since Harris, Hughes
and others described the clinical features of the antiphos- lupus anticoagulant and anticardiolipin antibodies. The
pholipid antibody syndrome (APS) [1–3]. Since then, lupus anticoagulant is detected in coagulation assays as
the syndrome originally scorned as a “black swan” or a it slows the rate of thrombin generation by perturbing
laboratory error has evolved as a distinct clinical entity interactions that require phospholipid, thus acting as an
[4] that is associated with protean clinical manifestations anticoagulant. The clue to the presence of a lupus antico-
such as arterial and venous thrombosis, recurrent abor- agulant is often an increased partial thromboplastin time
tions, and thrombocytopenia. Renal manifestations of (PTT) that fails to correct on mixing studies with normal
this syndrome have recently received more attention as plasma. The anticardiolipin antibodies, in contrast, are
the kidney appears to be a major target organ in both recognized by the ability to bind anionic phospholipids
primary and secondary APS. Although more prevalent in solid-phase immunoassays. Thus, anticardiolipin and
in patients with systemic lupus erythematosus (SLE), lupus anticoagulant are distinct but complementary tests
antiphospolipid antibodies (APAs) occur in patients for APAs. The genesis of APAs may involve both auto-
without other manifestations of autoimmune disease, the immune and alloimmune reactions. Alloimmune APAs
so-called “primary” APS. The preliminary classification may be observed following an infection such as hepatitis
and criteria for diagnosis of APS were published in 1999 C, Lyme disease [8–10], human immunodeficiency virus
infection (HIV), or in association with lymphoprolifera-
tive disease, and appear to have a weaker associationKey words: Antibodies; antiphospholipid; thrombosis; renal failure; hy-
pertension; lupus anticoagulant; anticardiolipin; graft non-function; SLE. with thrombotic complications [8, 9]. Autoimmune APAs
bind phospholipid epitopes in the presence of a cofactor
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affected. Thrombosis may affect deep leg veins, as well major platelet membrane glycoproteins [19, 20]. The
anti-platelet effects of APAs have been suggested to beas those of the skin, lungs, kidney, central nervous sys-
tem, and placenta. Thrombocytopenia is quite common. analogous to that observed in heparin-induced thrombo-
cytopenia [20], as 2-GPI binds to exposed anionic phos-While the association between these APAs and throm-
bosis is now well established, the unresolved central issue pholipids on the surface of activated platelets. Platelets
circulate in an increased state of activation in APS, butin both primary and secondary APS is how antibodies
against phospholipids lead to increased tendency to it is unclear if this is a cause or effect of thrombosis.
APAs also show substantial reactivity against endothe-thrombosis. In the case of lupus anticoagulant, this effect
appears paradoxical since an anticoagulant would be ex- lial cells. [21] In vitro data suggest that this reactivity of
APAs against endothelial cells involves both 2-GPI-pected to cause bleeding, not thrombosis. Phospholipid-
dependent coagulation reactions include the following dependent and independent mechanisms. Since virtually
any of the biologic processes that involve or requirereactions: (1) tissue factor-factor VII (VIIa) mediated
activation of factors X and IX; (2) factor IXa and factor phospholipids may be affected by the presence of anti-
bodies that bind to the phospholipids (either directly orVIIIa activation of factor X to factor Xa; and (3) factor
Xa and factor Va activation of prothrombin to thrombin via cofactors), any proposed APA-mediated effect based
on in vitro studies must be evaluated for in vivo rele-(see Fig. 1). The lupus anticoagulant appears to act by
limiting the amount of phospholipid available to support vance. Some of these effects are discussed below and
summarized in Table 1.these reactions, and thus prolonging the coagulation
times. A major advance in the understanding the throm-
bophilic effect of these antibodies occurred when two
PATHOGENESIS OF THROMBOSIS IN APS
groups led by McNeil et al [11] and Galli et al [12]
The precise mechanism by which the presence ofindependently observed that the major antigen (cofac-
APAs induces thrombosis is not completely understood.tor) for APA is a plasma protein, apolipoprotein H, or
Experimental and human data suggest that thrombosis2-GP1. This protein, a glycosylated single-chain plasma
induced by APAs may involve changes at the followingprotein composed of 326 amino acids with a molecular
sites: (1) dysregulation of coagulation; (2) platelet acti-weight of 50 kD, is a weak anticoagulant that binds to
vation; or (3) endothelial injury, disordered transmem-anionic phospholipids and inhibits the contact phase of
brane signaling, and microvasculopathy. These putativecoagulation and the activity of platelet prothrombinase.
pathophysiologic changes are summarized in Table 1.The exact nature of these epitope(s) remains uncertain.
Thus, these antibodies induce a hypercoagulable state,Data from this laboratory however, show that though
which meets Virchow’s triad for thrombosis (that is, ab-2-GPI increases antibody binding to phospholipid, it is
normal rheology, tissue injury and abnormal blood con-not an absolute prerequisite for binding [13]. Other data
stituent(s) for thrombogenesis) [22]. Data from our insti-suggest that monoclonal antibodies with lupus anticoag-
tution have shown that the thrombogenic effects of theseulant activity can increase the binding of 2-GPI to phos-
antibodies are not confined to human APA, but havepholipid [14]. This process then interferes with essential
also been shown for antibodies induced in mice [23].phospholipid-dependent steps in coagulation, especially
There is substantial evidence that endothelial cell injury/the assembly of the tenase and prothrombinase com-
activation plays a role in both in vitro an in vivo modelsplexes on anionic phospholipids. Consistent with these
of APS [23–25]. Nakamura et al showed that lupus anti-observations, thrombosis has been induced experimen-
coagulant can induce apoptosis in human umbilical endo-tally by immunoglobulins (Ig) IgG, IgM, and IgA from
thelial cells [21]. In their study, annexin V was necessarypatients with APS [15]. Proteins besides 2-GPI have
for induction of apoptosis. Recent data suggest that en-also been implicated in antiphospholipid antibody activ-
dothelial cell activation in APS may involve enhancedity. Patients with positive serology for antibodies to
expression of adhesion molecules such as intercellular2-GPI often have positive anticardiolipin assays, while
cell adhesion molecule-1 [1CAM-1], vascular cell adhe-serum samples positive for lupus anticoagulant but nega-
sion molecule [VCAM-1], and E selectin [26, 27]. Thetive for anticardiolipin appear not to exhibit binding to
fact that arteries, veins, and capillaries are potential2-GPI [16, 17]. Substantial heterogeneity exists among
thrombotic sites in patients with APA reflects the com-APAs as they react with other hemostatic plasma pro-
plexity of the underlying pathophysiologic mechanisms.teins, with platelets and vascular endothelial cells. Alter-
However, thrombotic episodes are generally either ve-ations of tissue factor activity [18], as well as the inhibi-
nous or arterial in a given patient, but not both. Whiletion of activated protein C and protein S by plasma
venous thrombotic events with APAs likely result fromcontaining APAs, represent potentially thrombophilic
perturbations of the protein C/protein S regulatory sys-changes that have been shown by other investigators.
tem [17, 24, 28], platelet activation appears to play aWhile binding of APAs to platelets appear to be depen-
dent on 2-GPI, other autoantibodies react with the central role in arterial thrombosis in APS. Other poten-
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Fig. 1. Control of coagulation showing the role
of phospholipids and sites of potential antiphos-
pholipid antibody (APA) action. Three critical
steps of the cascade are catalyzed by phospho-
lipids: (1) the tenase complex; (2) the prothrom-
binase complex; and (3) the protein C activation
complexes. Activation of the extrinsic or intrin-
sic pathway leads to conversion of factor X to
Xa. Factor Xa forms a complex with factor Va
and prothrombin on a phospholipid template
(prothrombinase complex) and this results in
thrombin generation from prothrombin. Acti-
vated protein C inactivates factor Va and factor
VIIIa in the presence of protein S and phospho-
lipids. APAs may affect all the pathways indi-
cated with an asterisk, resulting in a procoagu-
lant effect or in a “lupus anticoagulant effect”
(by inhibition of conversion of prothrombin into
thrombin).
Fig. 2. Kidney biopsy findings in 35-year-old woman with antiphos-
pholipid antibody syndrome (APS) nephropathy and systemic lupus
erythematosus (SLE) who developed rapidly progressive renal failure.
The biopsy findings of glomerular and arteriolar thrombosis, clearly
suggest that APS nephropathy caused the renal failure, rather than
lupus nephritis. (A ) Arteriole with recent thrombus (arrows) (hema-
toxylin and eosin stain; magnification400). Reprinted from reference
[46] with permission. (B ) Glomerular capillaries in same patient are
filled with fibrin thrombi (hematoxylin and eosin stain; magnification
200). (C ) Glomerular capillaries occluded by agglutinated red blood
cells.
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Table 1. Pathophysiologic changes contributing to thrombosis in APS
Abnormality Comments References
Persistent activation of coagulation Increased markers of thrombin generation have been observed; [8, 13]
increased levels of plasminogen activator inhibitor-1 (PAI-1)
Interference with the anticoagulant effect of 2-GPI Poor association of levels of 2-GPI with thrombosis; affinity [8–10]
of APA from patients for 2-GPI may be low
Inhibition of fibrinolysis, activated protein C resistance Increased clot thickness observed in animal model of APS [15]
Increased plasma concentration of tissue factor APAs enhance endothelial release of tissue factor [16]
Endothelial cell injury Lupus anticoagulants induce apoptosis in human umbilical vein [21]
endothelial cells
Cellular activation involving platelets, monocytes, APAs up-regulate expression of adhesion factors ICAM, VCAM [23–25]
endothelial cells
Inflammation, accelerated atherosclerosis APAs increase production of arachidonic and metabolites [26]
Abbreviations are: APS, antiphospholipid antibody syndrome; 2-GPI, beta 2-glycoprotein I; ICAM, intercellular adhesion molecule; VCAM, vascular cellular
adhesion molecule.
Table 2. Renal syndromes associated with APAs
Abnormality Comments References
SLE Glomerular thrombosis (TMA) [31, 32, 34]
? worsens outcome [40]
Renal infarct and vein thrombosis [47]
Acute renal failure May be reversible or irreversible
Renal vein thrombosis [55, 56]
Renal artery thrombosis/infarction [64]
Pregnancy-related renal failure [36]
Glomerulonephritis With IgA deposits [53]
TMA TTP/HUS [37, 42, 43]
Renovascular/malignant hypertension Renal artery stenosis may be unilateral or bilateral [68–74]
Proteinuria Variable from mild to nephrotic [60]
Chronic renal disease Vascular access thrombosis [89–92]
High prevalence in hemodialysis
Renal transplantation Graft thrombosis and allograft failure [93–96, 97, 100, 101]
APAs may be acquired post-transplant
Increased morbidity
Abbreviations are: SLE, systemic lupus erythematosus; TMA, thrombotic microangiopathy; APA, antiphospholipid antibodies; HUS, hemolytic uremic syndrome;
TTP, thrombotic thrombocytopenic pupura.
tially thrombogenic effects involve inflammation and hypertension; renal cortical necrosis; thrombotic mi-
croangiopathy; progressive chronic renal failure; as wellatherosclerosis [29]. Taken together, these experimental
data suggest that thrombosis in association with APAs as thrombosis in patients with renal allografts (Table 2).
involves interference with endogenous anticoagulant sys-
tems (such as protein C, annexin V, or vascular anticoag-
ANTIPHOSPHOLIPID ANTIBODIESulant alpha), cellular activation (involving platelets, en-
IN SLE-ASSOCIATED NEPHRITISdothelial cells, and leukocytes), persistent activation of
Conley and Hartman initially described the presencecoagulation system due to tissue factor activation and
of lupus anticoagulant in SLE patients in 1952 [30]. Sub-inhibition of the antithrombin III pathway, as well as
sequently, Bowie et al described thrombosis occurringinhibition of fibrinolysis (see Table 1).
in patients with circulating anticoagulants in a seminal
paper in 1963. [31] These observations of the association
RENAL SYNDROMES IN APS of APA with glomerular and arterial thrombosis in SLE
were extended over the next two decades by Kant et al,The kidney manifestations of APS may result from
thrombosis occurring at any location within the renal who reported a strong association between the presence
of lupus anticoagulant and the presence of glomerularvasculature, that is, in the renal artery trunk or branches,
intra-parenchymal arteries and arterioles, glomerular thrombi in renal biopsy specimens systematically per-
formed in SLE patients seropositive for lupus anticoagu-capillaries, and the renal veins. The resulting clinical
syndromes consists of variable degrees of proteinuria; lant [32]. While the precise origin of APAs in SLE is
unclear, their presence appears to consistently correlateexacerbation of SLE nephropathy; acute renal failure;
systemic hypertension, ranging from mild to accelerated with the occurrence of renal thrombotic microangiopa-
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thy (TMA). It is possible that these antibodies are gener- patients, that the presence of anticardiolipin antibody
and/or glomerular thrombi portends a worse renal out-ated by autoimmune responses akin to that which gener-
ates anti-nuclear antibodies (ANA). In a meta-analysis come, as patients with APA-positivity had significantly
more crescents, more sclerosis, and more glomerular ne-of 21 studies by Love and Santoro, an average prevalence
of 44% for anticardiolipin antibodies and 34% for lupus crosis [43]. This finding does not, however, prove a causal
relationship between inflammatory lupus renal lessionsanticoagulant, respectively, was documented in patients
with SLE [33]. The proportion of SLE patients with both and APA positivity. Moreover, Perez-Vaquez et al have
suggested that the prevalence of APS in SLE increaseslupus anticoagulant and anticardiolipin antibodies varies
from as high as 61 to 91% [32, 33–35] to about 15 to with duration of follow-up and on the number of samples
tested for APAs [44]. This finding further confounds the30% in other series, although not all of them have APS.
This wide variation in incidence reflects differences in interpretation of the relationship between APAs and
lesions of lupus nephritis. It is interesting that loss ofassay methods and case-mix of patients. The morbidity
associated with APAs in SLE has been a subject of con- renal function in SLE patients with APAs can also occur
without evidence of lupus nephritis due to APS [45]. Insiderable controversy [36–39]. While some data show
that TMA occurring in SLE patients with APAs was this situation, distinguishing between renal failure in SLE
due to nephritis (immune-complex disease) from thatassociated with worse prognosis, Naiker et al recently
confirmed a high prevalence of APAs in South African die to APS (glomerular thrombosis) can only be accom-
plished by kidney biopsy [46] (see Figure 2). This distinc-patients with lupus nephritis (45%), but found that the
presence of these antibodies per se appeared not to tion is critical as the treatment for each syndrome is
different. Aggressive lupus nephritis requires cytotoxicchange outcome [38], except for an increased incidence
of thrombocytopenia and renal vascular thrombosis. therapy, whereas APS nephropathy benefits from antico-
agulation. The nephropathy of APS occurring in theThese thrombotic events involved large arteries and
veins as well as the glomerular and intrarenal arteries course of SLE is the most common form of secondary
APS. In one study of a cohort of 100 patients withand arterioles. However, the study is limited by the fact
that these observations were based on a study of only SLE, APS nephropathy was observed in 63% of patients
with APS (abstract; Daugas E et al, J Am Soc Nephrol18 patients. Previously, Kincaid-Smith et al had reported
the occurrence of pregnancy-related acute renal failure 10:A99, 1999). In a recent systematic review of renal biop-
sies in another 114 patients with SLE, the same investiga-in 12 women (only two of whom had lupus nephritis)
caused by TMA in relation to lupus anticoagulant [36]. tors studied the lesions of secondary APS nephropathy
co-existing with those of lupus nephritis. They found sec-It is unclear at present if APA are initiators or acceler-
ators of arterial lesions in TMA, but both roles may ondary APS nephropathy in 36% of this cohort of SLE
patients, even though only 22% of their patients hadbe involved. It should be emphasized that the frequent
absence of immunoglobulin deposits in vessels involved APS [47]. This higher proportion of APS nephropathy
raises the possibility that renal-limited microvascular dis-in TMA suggests that thrombosis may be due to mech-
anisms other than immune-complex disease. In most ease may occur in the course of SLE in some patients.
The strengths of this study include a fairly large sampleseries [38–40], more glomerular thrombi are found in
those SLE patients with APAs than those without APAs, size (114 patients), as well as a strict definition criterion
for APA. This study also found greater correlation be-suggesting an increased morbidity, mostly related to
TMA, although these APAs do not affect the World tween lupus anticoagulant positivity and intrarenal throm-
bosis than was found in patients seropositive for anticar-Health Organization’s (WHO) histologic classification.
In the same area, it is unclear at this time if these antibod- diolipin antibodies. In addition to the TMA lesions seen
acutely in APS nephropathy associated with SLE, otheries affect the response to chemotherapy in lupus nephri-
tis; although microvasular lesions of SLE, in general, lesions such as fibrous intimal hyperplasia, and focal
cortical atrophy have also been observed in the affectedare considered to be independent risk factors for the
progression to end-stage renal disease (ESRD) [41]. An kidneys [47]. An aggressive vasculopathic state with wide-
spread thrombosis called catastrophic antiphospholipidarea of on-going controversy relates to the association
between the APS-associated lesions (such as glomerular syndrome (CAPS) may also occur in SLE [46, 48]. This
syndrome is described in greater detail in the discussionthrombi) and those of lupus nephritis. Miranda et al
found no association between the presence of these glo- of primary APS below. Hughson et al reported on the
outcome of treatment in three SLE patients with renalmerular thrombi and severity/activity of lupus nephritis
[40]. However, only nine of their patients were positive TMA and APS [37]. Renal failure and thrombocytopenia
resolved in each case following therapy with plasmapher-for APAs. These findings support earlier observations by
Farrugia et al, who equally found no association between esis, prednisone, and anticoagulation [37]. The associa-
tion between the presence of APAs in SLE and renalAPAs and the type of lupus nephritis lesion [42]. In
contrast, Bandari et al suggest from their study of 51 transplant outcomes, as well as other renal complications
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such as renal vein thrombosis and renal infarction, is brane adjacent to the endothelium. However, this sug-
gestion was based on a biopsy series of eight patientsdiscussed below. In some cases, chronic lesions of APS
nephropathy (such as fibrous intimal hyperplasia and and must await confirmation in larger biopsy series. In
CAPS, renal pathologic findings included TMA [51, 52,focal cortical atrophy) may co-exist with lesions of lupus
glomerulopathy [47]. The balance of the evidence at this 60], although crescentic glomerulonephritis was ob-
served in one case [63]. Renal involvement in the formtime favors the possibility that the occurrence of APS
nephropathy in patients with lupus nephropathy may of ARF and/or hematuria has been observed in 14% of
a large series of patients with CAPS [59]. TMA may beincrease the risk of progression to ESRD, even though
the WHO classification is unaffected. In the largest series the initial clinical manifestation of both primary APS
and secondary APS. Thus, APS should be considered inpublished to date [47], these patients had higher creati-
nine at time of diagnosis, increased interstitial fibrosis, the differential diagnosis of hemolytic uremic syndrome
(HUS), including pospartum cases [65, 66]. It has beenand a higher prevalence of hypertension, as discussed
later. No study, to our knowledge, has addressed the suggested by some that APAs may be generated in re-
sponse to thrombosis, rather than being the cause ofrelative prevalence of both TMA and large-vessel occlu-
sive disease in SLE patients with or without APS. thrombosis, but the evidence appears to favor a causal
role for APAs in the genesis of TMA in this syndrome.
RENAL DISEASE IN PRIMARY APS
APA IN SYSTEMIC HYPERTENSIONIn contrast to the well-described nephropathy associ-
ated with SLE and APS, it was not widely appreciated Hypertension is a common feature of the primary and
secondary APS [47, 49]. In the series of primary APSthat the primary APS could lead to nephropathy until
recently. The studies of the renal lesions in primary APS reported by Nochy et al, hypertension was present in
93% of their patients and was sometimes the only clinicalhave enabled investigators to observe the lesions due to
APS in pure form [47, 49–54], without the confounding sign suggestive of nephropathy [49]. In the secondary
APS series reported by Kleinknecht et al, all patientseffect of co-existing inflammatory changes. Several pa-
tients in these reports presented with acute renal failure with SLE and APS had severe hypertension with renal
insufficiency [67]. Thus, hypertension appears to be a(ARF). The precise pathogenesis of ARF in the primary
APS has not been clearly delineated, but is likely to be marker of nephropathy in both primary and secondary
APS. No study to our knowledge has addressed the prev-multifactorial. It may result from TMA, renal cortical
necrosis, renal infarction, renal vein thrombosis [55, 56], alence of APAs in an unselected population of patients
with essential hypertension. Hypertension in APS mayor in the unique aggressive vasculopathy, CAPS [57–63].
This is associated with multi-organ failure and wide- often be severe, with some patients presenting with hy-
pertensive emergencies. Rarely, hypertension associatedspread thrombotic diathesis. The renal lesions of the
primary APS nephropathy are identical to those seen with APS may be associated with microangiopathic he-
molytic anemia. It needs to be emphasized that bothin other TMAs, including postpartum renal failure and
sclerodermal renal crisis, with severe narrowing of the microvasculopathy and/or occlusion of the main trunk
of the renal artery can contribute to malignant hyperten-interlobular arteries and afferent arterioles. Predictably,
renal ischemia follows these diffuse thromboses. In a sion in the APS. Caccoub et al described five patients
with APS complicated by hypertensive crises who allfew cases, mesangial IgA deposition has been described
[53, 54]. Occasionally, thromboses occur in the large had normal magnetic resonance angiograms of the renal
vessels [68]. Three of their patients underwent contrastrenal arteries leading to renal infarcts [64]. The urine
sediment typically contains few cells or casts, and the angiography, which showed distal microangiopathy, but
no stenosis nor thrombosis of the main renal arteries.level of proteinuria varies from mild to nephrotic. The
histologic lesions associated with primary APS-related High-dose steroids (prednisone, 1.5 mg/kg/day) and anti-
coagulation led to rapid resolution of hypertensive crisesnephropathy have been well characterized and include
arteriosclerosis (75%); fibrous intimal hyperplasia (75%); in three of their patients. Five other reports have docu-
mented occlusion of main renal arteries leading to reno-tubular thyroidization (75%); arteriolar occlusions (68%);
TMA (31%), and organizing thrombosis (37%) [49]. vascular hypertension [68–74]. Most of the patients re-
ported with main renal artery stenosis had had very highSome novel glomerular ultrastructural changes have re-
cently been proposed to be pathognomonic for APS ne- titers of APAs, but in one case the titers were moderate
[64]. The outcome of renovascular hypertension withphropathy [62]. On light microscopy, the silver stains
show a combination of glomerular basement membrane APS appears to be good with treatments like anticoagu-
lation, with or without percutaneous balloon angioplasty,wrinkling and reduplication. By electron microscopy, re-
dundant wrinkled segments of basement membrane are leading to recovery of renal function and return to nor-
mal blood pressure [68–74]. The contribution of undiag-accompanied by a “new,” straighter thin basement mem-
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nosed APS in cases of ESRD assumed to be due to pathogenic [84–87], other studies have suggested that
APAs are associated with hemodialysis vascular accessessential hypertension is unknown. That the renin-angio-
tensin system appears to be activated in malignant hyper- thrombosis [88–91]. Whether both anticardiolipin anti-
bodies and lupus anticoagulants are equipotent in caus-tension due to APS is supported by data showing a posi-
tive catopril test in those with large vessel renal artery ing recurrent access thrombosis is unclear at this time.
Some studies suggest that both lupus anticoagulants andstenosis, as well as positive staining for renin containing
cells in some biopsied subjects [49]. anticardiolipin antibodies are associated with an in-
creased risk of vascular access thrombosis [88, 89], while
other studies have verified this relationship only with
APA IN END-STAGE RENAL DISEASE
lupus anticoagulation [86, 90]. Other unresolved issues
Data are few and conflicting concerning the preva- at this time concerning vascular access thrombosis with
lence and risk factors for APAs in ESRD. These differ- APAs include whether rates of occlusion of native arte-
ences probably depend on the patient mix and assays riovenous fistula thrombosis are identical to those of poly-
used for diagnosis. Patients with ESRD have higher fre- tetrafluoroethylene (PTFTE) grafts, or whether APAs
quency of positivity for APAs compared to the general cause in-dwelling catheter thrombosis, and if prophylac-
population [75–78]. tic anticoagulation would prevent these events. How-
Moreover, the prevalence of lupus anticoagulant was ever, on the strength of the epidemiologic and clinical
higher among patients treated by hemodialysis (30%), association of these antibodies, it would appear prudent
compared to those treated by conservative (non-dialytic) to incorporate APA testing into the diagnostic evalua-
approach. Subsequently, Sitter, Spannal, and Schiffl re- tion of recurrent thrombotic episodes on patients receiv-
ported that the prevalence of APAs were higher in he- ing hemodialysis [88–91].
modialysis patients compared to those on continous am-
bulatory peritoneal dialysis (CAPD) [77]. This higher
APAs IN RENAL TRANSPLANTATIONprevalence in hemodialysis has been confirmed by others
[78]. Quereda et al in a prospective study of 138 patients In renal transplant patients, the incidence of APAs
may also be increased, even in those without SLE [92].with nephropathy, found that the prevalence of APAs
was higher in patients with SLE (34%) than in those with In this study of patients without SLE, a prevalence of
28.1% was documented. Patients with and without APAschronic primary glomerulonephritis (9%) and lowest in
patients with non-immunologically mediated renal dis- did not differ in age, gender, underlying disease, immu-
nosuppressive regimen, serum creatinine concentration,eases (2.6%) [79]. The origin of APAs in ESRD patients
is unclear. It has been postulated that uremia is a form and platelet count. Of these APAs, 65.4% were acquired
in the pre-transplant period, while 15.7% acquired APAsof immunodeficiency in which autoimmunity may de-
velop as a result of altered immune function [80]. Some during the post-transplant period. Interestingly, 19 pre-
transplant APAs disappeared in 52.7% of patients inhave suggested that dialysis membranes generate APAs
due to incompatibility. In the study by Garcia Morton that series after transplant. The genesis of APAs after
renal transplant is unclear. Both pre-transplant and post-et al [78], patients dialyzed with cuprophane membranes
had a greater incidence of APAs than those dialyzed transplant APAs were associated with thrombosis affect-
ing the dural, femoral, and transplant veins.against more biocompatible membranes. However, in a
larger study by Brunet et al, there was no relationship In the case of SLE patients with APAs in renal trans-
plantation, their survival is worse than those of SLEbetween the APAs and the type of dialyzer used [80].
Other suggested reasons for generation of APAs in renal transplant patients without APAs [93]. Because of
this, Joseph, Radhakrishn, and Appel have suggestedESRD patients include trauma to blood passing through
the hemodialysis circuit, as observed in recipients of left that patients with SLE who have APAs require attention
in the post-transplant period to detect possible throm-ventricular assist devices [81] and induction by microbial
agents [82] or their products, such as endotoxins present botic events and/or consider prophylactic anticoagula-
tion [94]. Stone, Amend, and Criswell studied the clinicalin dialysate. If this were true, one would expect a correla-
tion between prevalence/titers of APAs and length of events in 96 consecutive patients with SLE after renal
transplantation [95]. They observed positivity for APAstime on dialysis. Such a relationship has not been shown
at this time. Moreover, not all patients exposed to same in 29.1%. Among these, 60% had clinical events related
to APAs, including deaths related to APS (10%); deepdialysate develop APAs. Although the precise mecha-
nisms involved in the genesis of APAs in ESRD are venous thrombosis and pulmonary embolism (24%);
strokes (16%); renal artery or renal vein thrombosisunknown, they appear to mostly 2-GPI-independent
[83]· Substantial controversy surrounds the precise risks (16%); and fetal loss (12%) [95].
Although APAs in hepatitis C-positive ESRD patientsassociated with the presence of APAs in ESRD patients.
While some studies suggest that these antibodies are not appear to be non-pathogenic, preliminary data suggest
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Table 3. Testing for antiphospholipid antibodiesthis may not be the case in post-renal transplantation,
as these patients may be at increased risk for allograft Tests for lupus anticoagulants
CriteriaTMA [96]. Anecdotal case reports also suggest that pa-
Prolongation of phospholipid-dependent coagulation testtients with primary APS who undergo renal transplanta-
Evidence of an inhibitor shown by mixing studies
tion may also have increased risk for graft failure [97]. Confirmation of the phospholipid-dependent nature of the inhibitor
ScreeningHow APAs may be acquired after transplantation is curi-
APTTous, but is as yet unexplained. None of these patients
Dilute Russel viper venom time (DRVVT)
were on drugs such as chlorpromazine, hydralazine, or Kaolin cephalin clotting time (KCT)
TTIprocainamide that can induce these antibodies. It has
Tests for anticardiolipin antibodiesbeen suggested that these APAs may be related to post-
Solid-phase ELISA immunoassay for IgM, 1gG, 1gA
transplant infection or autoimmune reactions to infec- -2-glycoprotein I (2-GPI)
ELISA for detection of other negatively charged phospholipidstions. Consistent with these observations, high levels of
ELISA is enzyme-linked immunosorbent assay.APAs are associated with cytomegalovirus infection in
unrelated bone marrow and cord blood allogeneic stem
cell transplantation [98].
Other studies have addressed the impact of APAs
renal allograft [107]. This patient lost two renal allograftson renal allograft failure [99–101]. In one study Wagen
in the first month after renal transplantation. The riskKnecht et al reported significantly more APAs in pa-
of early renal allograft loss in patients with ESRD withtients with early renal allograft failure than in patients
APAs who received renal transplants without hemodial-with functioning grafts. In that study, 57% final cross-
ysis was 100% in the study of Wagen Knecht et al, sug-matched sera from patients with early nonfunction were
gesting a possible protective role for renal allograftpositive for 1gG, 1gM, and 1gA APAs [99]. Thus, it is
thrombosis by a period of hemodialysis. The reason forpossible that testing for APA may identify certain pa-
the possibly protective effect of a hemodialysis history istients at risk for allograft failure. Biopsies of these failed
unclear, but it is likely that prolonged exposure to heparinallograft kidneys from APA-positive patients showed
with hemodialysis may be responsible. Consistent withthrombi in nine patients and infarction in five. However,
these observations, in vitro studies show that heparin canthese patients also received OK T3 induction therapy,
inhibit or neutralize APA binding [108]. Other possiblewhich may have induced renal allograft thrombosis [102],
mechanisms of renal allograft dysfunction in APA-posi-even though the same OK T3 indication therapy was
tive patients include allograft glomerulonephritis, renalused in patients with functional allografts. Thus, the im-
vein thrombosis, and post-transplant ARF [109].pact of immunosuppression in renal allograft thrombosis
Unresolved questions include whether patients withmust be excluded to better quantify the impact of APAs
APAs with normal renal function should serve as kidneyin early allograft failure. However, a role for coagulation
donors, in light of possible future renal complications.anomalies, such as factor V Leiden mutation, deficiencies
Recently, a case was reported of a patient who developedof protein C and S, as well as lupus anticoagulant in early
ARF requiring hemodialysis due to renal artery occlu-renal transplant failure, has been suggested by some
sion 6 years after donating a kidney to his mother [110].investigators [99]. Fischereder et al found that throm-
ARF in this patient was irreversible, and the patientbophilia represented a 3.5-fold increase in risk for 1-year
became dialysis-dependent.renal allograft loss [103]. Although the mechanism for
early graft failure in APA-positive patients is unclear,
perturbations of hemostasis appear plausible. In an im- MANAGEMENT OF THROMBOSIS IN APS
munocytochemical study of failed renal allografts, sig-
Diagnostic difficultiesnificantly more depletion of vascular antithrombin and
It is clear that APS shows substantial heterogeneityincreased fibrin deposition were observed by Tory et al
in clinical features, as well as the range of autoantibodies.in transplants that failed in the first month than those that
Accurate diagnosis is critical because of the high riskfailed 2 to 12 months or later after renal transplantation
of recurrent thrombosis. This heterogeneity mandates a[104]. No differences in cellular infiltrates were observed,
comprehensive approach to laboratory testing [111–114],thus excluding cellular rejection. This pattern of allograft
as shown in Table 3. Thus, it is recommended that whenloss with fibrin deposition in the absence of cellular infil-
APS is suspected, a panel of tests, including lupus anticoag-trates has also been observed in failed cardiac allografts
ulant, and anticardiolipin antibody, assays be performed.where depletion of vascular tissue plasminogen activator
and endothelial cell activation have been implicated [105,
Lupus anticoagulant assays106]. Wagen Knecht et al provide further proof of the
The common denominator of all lupus anticoagulantrole of APA in early renal allograft loss in their report
of a case in which they isolated APA from a thrombosed tests is that they detect the inhibition of phospholipid-
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dependent coagulation reactions, thus prolonging coagu- of 3.5 offers good protection against recurrences without
a major increase in hemorrhages. (abstract; Ruiz-Iras-lation times [9]. The term “lupus anticoagulant” is a
misnomer, since this phenomenon is not seen exclusively torza G et al, Arthritis Rheum 43:S313, 2000). The factors
that trigger recurrent thrombosis are poorly understoodin SLE patients. A number of methods have been used
to detect the presence of lupus anticoagulant, including [120]. While steroids may decrease APA titers, they do
not reduce the risk of thrombosis. Recently, it has beenmodifications of the activated partial thromboplastin
times (aPTT), the kaolin cephalin clotting time (KCT), shown that steroids may also potentiate the anticoagu-
lant effect of warfarin [121]. Scattered case reports sug-the dilute Russell viper venom time (dRVVT), and the
thromboplastin inhibition test (TTI). The dRVVT is con- gest that plasmapheresis is beneficial in APS patients
presenting with TMA [122, 123]. It should also definitelysidered to be one of the most sensitive tests for lupus
anticoagulant. be considered in the patients presenting with CAPS, as it
removes the pathogenic APAs, inducing the widespread
Tests for anticardiolipin antibodies thrombotic diathesis. The role of thrombolytics is unclear
at this time, although thrombolytic therapy improvedMost patients with APS are identified with elevated
anticardiolipin antibodies. The precursor for this assay, outcome in one patient with acute large-vessel occlusive
disease [124]. The role of hydroxycholoroquine and/orthe biologic false positive test for syphilis developed at
the Venereal Disease Research Laboratory, is itself an chloroquine in preventing thrombosis in APS is contro-
versial. Some data suggest that these drugs have anti-anticardiolipin test in which cardiolipin is the antigen.
High levels of anticardiolipin antibodies are predictive thrombotic actions. Platelet aggregation induced by aden-
osine diphosphate (ADP), collagen, and ristocetin canof an increased risk of thrombosis [8]. It should be em-
phasized that positive anticardiolipin antibodies assays be inhibited by chloroquine in a dose-dependent manner
[125–127]. Consistent with these observations, hydro-may be found in the asymptomatic “normal” population
with a prevalence that varies from 3 to 10% [8]. It should xychloroquine significantly diminished both thrombus size
and total time of thrombus formation in mice with APSalso be appreciated that in some cases of APA positivity
in patients with renal disease, such as in acute post- [128]. However, the effect of chloroquine in APS in hu-
mans is unclear. Experience with intravenous immuno-streptococcal glomerulonephritis, the presence of APAs
may be a marginal immunological phenomenon trig- globulins in treating APS is limited and uncontrolled.
Some data suggest that it is effective for the preventiongered by streptococcal infection, unrelated to the glo-
merular disease [115]. Other anticardiolipin tests include of recurrent pregnancy loss when therapies such as hepa-
rin and low-dose aspirin have failed [128-131]. Its roleantibodies against 2-GP1, the major protein cofactor
for APAs, and antibodies against phosphatidyl ethanol- in treating renal disease in APS is unknown at this time,
although intravenous immunoglobulin in combinationamine. Enzyme-linked immunosorbent assays (ELISAs)
for2-GP1 antibodies are considered to be more specific, with steroids and heparin improves survival in CAPS.
Recently, we showed that immunoglobulin decreases inbut less sensitive for APS than anticardiolipin assays
[111]. Clinical correlation is therefore necessary to de- vivo thrombosis and endothelial cell activation in animal
models of APS [131, 132]. Newer therapeutic modalitiescide the significance of a positive APA test. This compre-
hensive diagnostic approach (Table 3) often includes that deserve further investigation include prostacyclin,
fibronolytic agents such as tissue plasminogen activatorusing a combination of coagulation-based tests for lupus
anticoagulant and solid-phase ELISAs for anticardio- (TPA) and defibrotid. Some investigators have shown
that tolerance can be induced to experimental APS bylipin antibodies. Such an approach would help resolve
the “equivocal” cases of APS [116, 117]. syngeneic stem cell transplantation [132].
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